Published in Medical Letter on the CDC and FDA, March 27th, 2005
The VIGIV program is managed by DVC, LLC, a CSC company, for the U.S. Department of Defense joint vaccine acquisition program (JVAP) product management office.
VIGIV is the first FDA-licensed product for both DVC and the JVAP. The VIGIV program was granted fast track and orphan drug designation by the FDA. "Orphan" designation is a special status granted to a product that treats a rare disease or condition.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA